Analysis Of The Efficacy Of IFN-? Antiviral Therapy In 323 Patients With HBeAg-positive Chronic Hepatitis B

ObjectiveA retrospective analysis of 323 patients with HBeAg-positive chronic hepatitis B(CHB)who were treated with IFN?-2b antiviral therapy and follow-up clinical data for 5 years after drug withdrawal,to explore the efficacy and safety of IFN?-2b in treatment of HBeAg-positive CHB patients.MethodologyCollect the clinical data of 323 patients with HBeAg-positive CHB who were received IFN?-2b antiviral therapy from January 2010 to January 2014,According to the level of ALT,it was divided into ALT<2×ULN(groupA1 111cases),2×ULN?ALT?5×ULN(groupA2 111cases),ALT>5×ULN(groupA3 101cases),and according to the level of HBVDNA,it was divided into HBVDNA<7 lg copies/ml(groupB1 102cases)and HBVDNA?7 lg copies/ml(groupB2 221cases),Follow-up the dug withdrawal and after 3,6,12,18,24,36,48,60 months of HBVDNA negative conversion rates,HBsAg negative conversion rates,HBeAg seroconversion rates,virological relapse rates,clinical relapse rates and adverse drug reactions occurred during the treatment.Statistical analysis was performed by SPSS 23.0,P<0.05 was considered as statistical difference.Results323 patients with HBeAg-positive CHB were received IFN?-2b antiviral therapy at the time of dug withdrawal and after 3,6,12,18,24,36,48,60 months,HBVDNA negative conversion rates were 39.9%,40.2%,39.0%,36.2%,34.1%,33.4%,31.3%,30.7%,30.7%(the difference between groups A1,A2 and A3 were statistically significant P<0.05;the difference between groups B1 and B2 at the time of drug withdrawal and after3,6and 12 months were statistically significant P<0.05);HBsAg negative conversion rates were 6.2%,6.2%,6.2%,5.9%,5.9%,5.9%,5.6%,5.6%,5.6%(the difference between groups A1,A2 and A3 were not statistically significantP>0.05;the difference between groups B1 and B2 were not statistically significant P>0.05);HBeAg seroconversion rates were 28.2%,31.0%,32.8%,34.4%,33.7%,33.1%,32.8%,32.5%,31.6%(the difference between groups A1,A2,and A3 were statistically significant P<0.05;the difference between groups B1 and B2 were statistically significant P<0.05).At the time of 3,6,12,18,24,36,48,60 months after dug withdrawal,the sustained virological response(SVR)rates were 93.8%,86.0%,76.0%,71.3%,69.8%,64.3%,62.8%,62.8%(the difference between groups A1,A2 and A3 were not statistically significant P>0.05;the difference between groups B1 and B2 were not statistically significant P>0.05);virological relapse rates were 3.9%,7.8%,14.7%,18.6%,20.9%,27.9%,29.5%,30.2%;clinical relapse rates were 0%,3.1%,10.1%,14.0%,17.1%,21.7%,25.6%,26.4%.There were 238 cases(73.7%)of leukopenia,35 cases(10.8%)of thyroid dysfunction,5 cases(1.5%)of alopecia areata,1 case(0.3%)of sleep disorders,At the time of dug withdrawal 6 cases(1.9%)of severe thyroid dysfunction,1 case(0.3%)of blood glucose raised,all returned to normal after drug withdrawal.conclusion(1)IFN?-2b has a good effect and safety in the treatment of patients with HBeAg-positive CHB.323 patients with HBeAg-positive CHB during the treatment and after dug withdrawal can obtain a higher HBVDNA negative conversion rates,HBsAg negative conversion rates,HBeAg seroconversion rates,and a higher SVR rates after drug withdrawal.(2)IFN?-2b is effective in the treatment of patients with HBeAg-positive CHB,the higher levels of ALT and lower levels of HBVDNA viral load are more effective.